Unilateral microinjection of acrolein into thoracic spinal cord produces acute and chronic injury and functional deficits. (21st June 2016)

• Record Type: Journal Article
• Authors: Gianaris, Alexander; Liu, Nai-Kui; Wang, Xiao-Fei; Oakes, Eddie; Brenia, John; Gianaris, Thomas; Ruan, Yiwen; Deng, Ling-Xiao; Goetz, Maria; Vega-Alvarez, Sasha; Lu, Qing-Bo; Shi, Riyi; Xu, Xiao-Ming
• Is Part Of: Neuroscience. Volume 326(2016)
• Page Start: 84
• Page End: 94
• Publication Date: 2016-06-21
• Subjects: BBB Basso, Beattie, and Bresnahan locomotor rating scale -- ED1 ectodermal dysplasia -- GFAP anti-glial fibrillary acidic protein -- PBS phosphate-buffered saline -- SCI spinal cord injury -- WM white matter; acrolein -- aldehyde -- oxidative stress -- lipid peroxidation -- spinal cord injury; Neurochemistry -- Periodicals; Neurophysiology -- Periodicals; Neurology -- Periodicals; Neurochimie -- Périodiques; Neurophysiologie -- Périodiques; Neurochemistry; Neurophysiology; Electronic journals; Periodicals; Electronic journals; 612.8
• DOI: 10.1016/j.neuroscience.2016.03.054
• Languages: English
• ISSNs: 0306-4522

Abstract

Highlights: Acrolein microinjection produces dose-dependent tissue damage and motor deficits. Acrolein microinjection induces gliotic response and macrophage invasion. Acrolein could be an important contributor to secondary spinal cord injury. Acrolein could be a target for therapeutic intervention. Abstract: Although lipid peroxidation has long been associated with spinal cord injury (SCI), the specific role of lipid peroxidation-derived byproducts such as acrolein in mediating damage remains to be fully understood. Acrolein, an α-β unsaturated aldehyde, is highly reactive with proteins, DNA, and phospholipids and is considered as a second toxic messenger that disseminates and augments initial free radical events. Previously, we showed that acrolein increased following traumatic SCI and injection of acrolein induced tissue damage. Here, we demonstrate that microinjection of acrolein into the thoracic spinal cord of adult rats resulted in dose-dependent tissue damage and functional deficits. At 24 h (acute) after the microinjection, tissue damage, motoneuron loss, and spinal cord swelling were observed on sections stained with Cresyl Violet. Luxol fast blue staining further showed that acrolein injection resulted in dose-dependent demyelination. At 8 weeks (chronic) after the microinjection, cord shrinkage, astrocyte activation, and macrophage infiltration were observed along with tissue damage, neuron loss, and demyelination. These pathological changes resulted in behavioral impairments as measured by both the Basso, Beattie, and Bresnahan (BBB) locomotor rating scale and grid walking analysis. Electron microscopy further demonstrated that acrolein induced axonal degeneration, demyelination, and macrophage infiltration. These results, combined with our previous reports, strongly suggest that acrolein may play a critical causal role in the pathogenesis of SCI and that targeting acrolein could be an attractive strategy for repair after SCI.